Atrium Health Levine Children's Brenner Children's Hospital patient throws first pitch at Dash game
During his time at Brenner Children's Hospital, Jamon discovered his love for art. Prior to his diagnosis, Jamon enjoyed basketball and football, but after staying at the hospital he found a new passion. In February, Jamon worked with the Winston-Salem Dash team to create an ice cream inspired jersey to be worn by players during the Stand Up to Cancer game.
On Saturday, June 14, Jamon threw out the first pitch at the Winston-Salem Dash Stand Up to Cancer game. Later in the game, he was recognized for his bravery battling T-Cell Leukemia. Players also wore a special jersey designed by Jamon. He was excited to see his design come to life on the field.
'No matter what you're going through, keep pushing because God is going to make a way,' Jamon said. 'Trust the group of people supporting you, no matter how big or small your group is. Find a group of people that believe in you as much as you believe in yourself.'
Atrium Health Wake Forest Baptist is a pre-eminent academic learning health system based in Winston-Salem, North Carolina, and part of Advocate Health. Atrium Health Wake Forest Baptist's two main components are an integrated clinical system with locations throughout the region and
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline
AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a 'high-risk, high-reward' clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T therapy that overcomes limitations with current options. Currently approved therapies of this kind act by upgrading patient-extracted T cells' ability to fight cancer cells, but this method has financial and scalability hurdles, along with a lymphodepleting chemo requirement, curbing uptake. Capstan's lead asset, CPTX2309, is an in vivo targeted lipid nanoparticle (LNP) anti-CD19 CAR-T therapy that could solve these issues. AbbVie certainly sees the promise in the drug, paying $2.1bn upfront to take control of the CAR-T therapy alongside other preclinical programmes and the RNA payload-delivering technology used to create them. CPTX2309, being developed for the treatment of B-cell-mediated autoimmune diseases, is already being evaluated in a Phase I study (NCT06917742) with healthy volunteers. A preliminary look at the data from Capstan has revealed strong B-cell depletion – the aim of the treatment is to achieve an 'immune reset' by repopulation of healthy B cells. Investors shared positive sentiment in the acquisition, with shares in NYSE-listed AbbVie closing 1.7% higher at $185.62 on 30 June, the day the announcement was made. The big pharma has a market cap of $327.9bn. This is not the first in vivo CAR-T relationship that AbbVie has fostered, with a collaboration with Umoja Biopharma in January 2024. This partnership allows AbbVie to develop in-situ generated CAR-T cell therapy candidates in oncology using Umoja's VivoVecplatform. William Blair analyst Matt Phipps said in a research note: 'While CPTX2309 is still in early clinical development, we believe the acquisition shows a strategic effort by AbbVie to further strengthen its immunology franchise through novel, disease-modifying mechanisms. 'Given the stage of development, this asset clearly comes with clinical risk, but given the potential of in vivo CAR-T, which does not require lymphodepletion and has potential for greater manufacturing scalability, it offers significant long-term upside if successful.' Phipps, who described AbbVie's new asset as 'high-risk, high-reward,' said the purchase consolidates AbbVie's strong trading. The big pharma company has already shrugged off the loss of market exclusivity for its blockbuster Humira (adalimumab) by rolling out Skyrizi (risankizumab) and Rinvoq (upadacitinib). According to William Blair, forecast revenue rate from 2024 to 2029 growth rate for AbbVie trails only Eli Lilly and Sanofi, representing an 'attractive opportunity' for long-term investors. Capstan's CEO Laura Shawver said: "In vivo CAR-T represents a potential new treatment modality in medicine – embodying the transformative power of cell therapy with the accessibility and scalability of an off-the-shelf biologic. This technology has the potential to become a first-in-class platform to treat a wide range of autoimmune diseases.' Interius BioTherapeutics and Umoja Biopharma are two biotechs in the in vivo CAR-T arena that have assets in clinical trials targeting oncological indications. These assets also use lentiviral vectors to generate the cells in vivo, whereas Capstan is using mRNA. CPTX2309 is built on Capstan's targeted LNP platform to enable in vivo delivery of RNA payloads to target cells. CPTX2309 is made up of an anti-CD19 CAR mRNA payload inside an LNP. AbbVie's purchase comes just a few days after the US Food and Drug Administration (FDA) removed an access barrier for currently approved CAR-T therapies, regarded as a boost to the sector's outlook. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. "AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Journals
a day ago
- Business Journals
Wake Forest's Charlotte campus redefines medical education with inaugural class
When Wake Forest University School of Medicine Charlotte opens this July, Charlotte will welcome its first class of 49 medical students to the new campus in The Pearl innovation district. The program will debut a pioneering, case-driven curriculum that immerses students in real-world patient scenarios from day one—reshaping how future physicians are trained. This campus builds on the Winston-Salem-based program and makes problem-based learning the cornerstone of its educational approach. Students and faculty at both campuses share resources, research opportunities and rotations. The connection allows students and faculty to tap into the full resources of the school across both locations, says Roy E. Strowd, M.D., vice dean for undergraduate medical education at Wake Forest University School of Medicine, who travels weekly between both sites. 'There's not that traditional lecture piece that many would be familiar with from their training,' Strowd said. 'The week starts with a case, and that becomes the springboard for self-guided instruction with faculty oversight.' The medical community's response has been unprecedented. When Strowd started recruiting for the first 30 teaching positions, he received nearly 170 applications. With enrollment expected to reach approximately 100 students per class over the next five years, the first Charlotte students will work with as many as 1,000 area physicians during their final two years of clinical rotations. expand Anatomy instruction relies on advanced tools rather than traditional cadaver labs, which allows students to learn anatomy longitudinally throughout their training rather than in isolated blocks. Students use virtual reality systems and plastinated specimens. (Plastination refers to the process of replacing water and fat in biological tissue with durable plastics.) The students also begin ultrasound instruction from day one. 'Wake Forest University School of Medicine is going to have the ability to really change the landscape of what we know about medical education,' Strowd said. The Charlotte campus' home at The Pearl sits just steps from Atrium Health Carolinas Medical Center, a Level I trauma and academic hospital. That proximity supports early clinical exposure through advanced technology and specialized services. The Pearl also hosts IRCAD North America, a world-renowned surgical training center providing expertise in robotics and minimally invasive surgery. Ensuring educational excellence across both locations remains a priority. The School of Medicine maintains consistent academic standards across both campuses. Graduates from Charlotte and Winston-Salem complete the same exams, residency match benchmarks and graduation requirements. Student performance in courses and phases is closely monitored and used to refine instruction. expand This expansion responds to a clear regional need. Charlotte was the nation's largest city without a four-year medical school. North Carolina also has one of the biggest rural populations in the country. The School of Medicine graduates enter primary care at high rates, and many stay in state for residencies. Once both campuses reach full enrollment, the Wake Forest University School of Medicine expects to graduate about 245 doctors per year, making it the largest medical school in the state by enrollment. The model also expands research opportunities for medical students in both cities, with students and faculty engaging in basic science work primarily in Winston-Salem and implementation-based projects in Charlotte. Character development remains central to the School's mission. Like the Winston-Salem campus, the Charlotte campus will focus on developing physicians who demonstrate intellectual humility, curiosity, compassion and courage through community integration and strategic partnerships. 'We're not reinventing what's happening in Charlotte's medical community, we're becoming integrated into what's already there and helping it grow,' Strowd said.
Business Journals
a day ago
- Business Journals
Atrium Health Levine Children's Brenner Children's Hospital patient throws first pitch at Dash game
15-year-old Jamon King was diagnosed with T-Cell Leukemia in January of 2023. It started as a stomachache that wouldn't go away. His mother took him to the doctor seeking answers and learned the devastating news. Jamon immediately began his treatment at Atrium Health Levine Children's Brenner Children's Hospital. During his time at Brenner Children's Hospital, Jamon discovered his love for art. Prior to his diagnosis, Jamon enjoyed basketball and football, but after staying at the hospital he found a new passion. In February, Jamon worked with the Winston-Salem Dash team to create an ice cream inspired jersey to be worn by players during the Stand Up to Cancer game. On Saturday, June 14, Jamon threw out the first pitch at the Winston-Salem Dash Stand Up to Cancer game. Later in the game, he was recognized for his bravery battling T-Cell Leukemia. Players also wore a special jersey designed by Jamon. He was excited to see his design come to life on the field. 'No matter what you're going through, keep pushing because God is going to make a way,' Jamon said. 'Trust the group of people supporting you, no matter how big or small your group is. Find a group of people that believe in you as much as you believe in yourself.' Atrium Health Wake Forest Baptist is a pre-eminent academic learning health system based in Winston-Salem, North Carolina, and part of Advocate Health. Atrium Health Wake Forest Baptist's two main components are an integrated clinical system with locations throughout the region and
